Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:36 PM
Ignite Modification Date:
2025-12-24 @ 10:36 PM
NCT ID:
NCT00629135
Eligibility Criteria:
Inclusion Criteria:
* Patients who attained full age (18 years) with intra-abdominal abscesses documented by:
A) Laparotomy revealing intra-abdominal abscess or macroscopic gastrointestinal perforation OR
B) Suspected intra-abdominal abscess and scheduled for operation with at least three of the following criteria:
* fever,
* leucocytosis,
* symptoms referable to the abdominal cavity (nausea, pain),
* tenderness with or without rebound / abdominal wall rigidity,
* radiological evidence for abscess or gastrointestinal perforation.
Exclusion Criteria:
* Patients with the following:
* indwelling peritoneal catheter,
* presumed spontaneous bacterial peritonits,
* peripancreatic sepsis or infection secondary to pancreatitis,
* peptic or traumatic perforation of gastrointestinal tract of \< 24 h duration,
* traumatic perforation of the small or large bowel of \< 12h duration,
* transmural necrosis of the intestine due to acute embolic, thrombotic or obstructive occlusions,
* acute cholecystitis,
* appendicitis without perforation or abscess,
* required open abdomen techniques for management,
* gynaecological infection,
* known hypersensivity to any of the study drugs,
* lifethreatening disease with life expectancy of less than 48 hours,
* neutropenia with neutrophil count \< 1000 cells/µl,
* receiving chronic treatment with imunosuppressant therapy,
* HIV-seropositives with CD4 count \< 200 cells/µl,
* end stage hepatic cirrhosis CHILD PUGH C,
* central or peripheral neuropathy,
* bradycardia,
* symptomatic dysrhythmia in medical history,
* syndromes of QTc prolongation or use of concomittant medicaments reported to increase QT interval,
* disorder of the electrolyte balance,
* previous history of tendinopathy with quinolones,
* previously enrolled in the trial or use of any investigational drug within the previous 30 days
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00629135
Study Brief:
Protocol Section:
NCT00629135